CN115397420A - 阿立哌唑治疗的剂量起始方法 - Google Patents

阿立哌唑治疗的剂量起始方法 Download PDF

Info

Publication number
CN115397420A
CN115397420A CN202180025911.8A CN202180025911A CN115397420A CN 115397420 A CN115397420 A CN 115397420A CN 202180025911 A CN202180025911 A CN 202180025911A CN 115397420 A CN115397420 A CN 115397420A
Authority
CN
China
Prior art keywords
aripiprazole
oral
dose
patient
injection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180025911.8A
Other languages
English (en)
Chinese (zh)
Inventor
马修·哈林
王晓峰
王燕琳
阿拉什·劳菲尼亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=75581573&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN115397420(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Priority to CN202411916296.1A priority Critical patent/CN119792290A/zh
Publication of CN115397420A publication Critical patent/CN115397420A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hospice & Palliative Care (AREA)
CN202180025911.8A 2020-04-01 2021-04-01 阿立哌唑治疗的剂量起始方法 Pending CN115397420A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202411916296.1A CN119792290A (zh) 2020-04-01 2021-04-01 阿立哌唑治疗的剂量起始方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063003544P 2020-04-01 2020-04-01
US63/003,544 2020-04-01
PCT/JP2021/014194 WO2021201239A1 (en) 2020-04-01 2021-04-01 Methods for dose initiation of aripiprazole treatments

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411916296.1A Division CN119792290A (zh) 2020-04-01 2021-04-01 阿立哌唑治疗的剂量起始方法

Publications (1)

Publication Number Publication Date
CN115397420A true CN115397420A (zh) 2022-11-25

Family

ID=75581573

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202180025911.8A Pending CN115397420A (zh) 2020-04-01 2021-04-01 阿立哌唑治疗的剂量起始方法
CN202180026022.3A Pending CN115379842A (zh) 2020-04-01 2021-04-01 阿立哌唑注射制剂的施用方法
CN202411916296.1A Pending CN119792290A (zh) 2020-04-01 2021-04-01 阿立哌唑治疗的剂量起始方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN202180026022.3A Pending CN115379842A (zh) 2020-04-01 2021-04-01 阿立哌唑注射制剂的施用方法
CN202411916296.1A Pending CN119792290A (zh) 2020-04-01 2021-04-01 阿立哌唑治疗的剂量起始方法

Country Status (16)

Country Link
US (5) US20220160621A1 (https=)
EP (3) EP4125903B1 (https=)
JP (4) JP7584535B2 (https=)
KR (3) KR102732030B1 (https=)
CN (3) CN115397420A (https=)
AU (2) AU2021245713A1 (https=)
BR (2) BR112022018647A2 (https=)
CA (3) CA3136727A1 (https=)
ES (1) ES2995466T3 (https=)
HR (1) HRP20241574T1 (https=)
HU (1) HUE069157T2 (https=)
MX (2) MX2022012353A (https=)
PL (1) PL4125903T3 (https=)
TW (3) TWI865760B (https=)
WO (2) WO2021201238A1 (https=)
ZA (1) ZA202210633B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法
US20250387321A1 (en) 2023-03-17 2025-12-25 Otsuka Pharmaceutical Co., Ltd. Methods of dispersing aripiprazole injectable preparations
AU2024263986A1 (en) * 2023-04-26 2025-10-09 Otsuka Pharmaceutical Co., Ltd. Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1870980A (zh) * 2003-10-23 2006-11-29 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
US20150087654A1 (en) * 2013-09-24 2015-03-26 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired cyp2d6 or cyp3a4 enzyme function
US20190099494A1 (en) * 2012-04-23 2019-04-04 Otsuka Pharmaceutical Co., Ltd. Injectable preparation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
MX2009014115A (es) 2007-06-25 2010-04-21 Otsuka Pharma Co Ltd Microesferas que tienen estructura de nucleo/corteza.
JP2020520380A (ja) * 2017-05-16 2020-07-09 ボウ リバー エルエルシー 処置法
EP3761983A1 (en) * 2018-03-05 2021-01-13 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN108498456B (zh) 2018-05-16 2021-01-01 丽珠医药集团股份有限公司 一种阿立哌唑缓释微球及其制备方法
CN110327296B (zh) 2019-08-06 2021-10-22 深圳市泛谷药业股份有限公司 一种阿立哌唑长效注射制剂及其制备方法
TWI865760B (zh) 2020-04-01 2024-12-11 日商大塚製藥股份有限公司 阿立哌唑注射用製劑之投予方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1870980A (zh) * 2003-10-23 2006-11-29 大冢制药株式会社 控释无菌阿立哌唑注射剂和方法
US20190099494A1 (en) * 2012-04-23 2019-04-04 Otsuka Pharmaceutical Co., Ltd. Injectable preparation
US20150087654A1 (en) * 2013-09-24 2015-03-26 Otsuka Pharmaceutical Co., Ltd. Method of providing aripiprazole to patients having impaired cyp2d6 or cyp3a4 enzyme function

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
LESLIE CITROME等: "Aripiprazole Long-Acting Injectable Formulations for Schizophrenia: Aripiprazole Monohydrate and Aripiprazole Lauroxil"，Leslie Citrome等，Expert Review of Clinical Pharmacology", EXPERT REVIEW OF CLINICAL PHARMACOLOGY, vol. 9, no. 2, 19 December 2015 (2015-12-19), pages 169 - 186 *

Also Published As

Publication number Publication date
KR20220161403A (ko) 2022-12-06
HRP20241574T1 (hr) 2025-01-31
EP3941470A1 (en) 2022-01-26
CN119792290A (zh) 2025-04-11
TW202200141A (zh) 2022-01-01
EP4467194A3 (en) 2025-01-08
US20240374506A1 (en) 2024-11-14
TW202200142A (zh) 2022-01-01
ZA202210633B (en) 2025-01-29
JP7733000B2 (ja) 2025-09-02
MX2022012353A (es) 2022-10-31
JP2023520004A (ja) 2023-05-15
AU2021248212A1 (en) 2022-12-01
KR20240165486A (ko) 2024-11-22
WO2021201239A1 (en) 2021-10-07
KR20220161402A (ko) 2022-12-06
KR102732030B1 (ko) 2024-11-20
JP7584535B2 (ja) 2024-11-15
US20260034053A1 (en) 2026-02-05
AU2021245713A1 (en) 2022-12-01
MX2022012354A (es) 2022-10-31
US20230129919A1 (en) 2023-04-27
US20220160621A1 (en) 2022-05-26
CN115379842A (zh) 2022-11-22
BR112022018647A2 (pt) 2022-11-08
HUE069157T2 (hu) 2025-02-28
CA3136727A1 (en) 2021-10-07
JP2025020306A (ja) 2025-02-12
CA3163321A1 (en) 2021-10-07
BR112022018721A2 (pt) 2022-11-01
EP4125903B1 (en) 2024-10-09
EP4125903A1 (en) 2023-02-08
EP4467194A2 (en) 2024-11-27
TWI865760B (zh) 2024-12-11
TW202523329A (zh) 2025-06-16
WO2021201238A1 (en) 2021-10-07
EP4125903C0 (en) 2024-10-09
US20230225962A1 (en) 2023-07-20
CA3163321C (en) 2023-12-19
JP2023519425A (ja) 2023-05-10
JP2025176037A (ja) 2025-12-03
PL4125903T3 (pl) 2025-02-03
ES2995466T3 (en) 2025-02-10
TWI906279B (zh) 2025-12-01
CA3212191A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
CN115397420A (zh) 阿立哌唑治疗的剂量起始方法
WO2019175657A1 (en) Capsid assembly modulator dosing regimen
HK40122823A (zh) 阿立哌唑治疗的剂量起始方法
WO2024145288A2 (en) Methods of administering r-ketamine
HK40080999A (en) Methods for dose initiation of aripiprazole treatments
HK40120297A (en) Methods for dose initiation of aripiprazole treatments
EP4301367A1 (en) Use of luvadaxistat for the treatment of cognitive impairment
HK40081123B (en) Methods for dose initiation of aripiprazole treatments
HK40081123A (en) Methods for dose initiation of aripiprazole treatments
WO2024225441A1 (en) Dose initiation for schizophrenia or bipolar i disorder treatment with aripiprazole
HK40128859A (zh) 用阿立哌唑治疗精神分裂症或i型双相障碍的剂量启动
US20260115131A1 (en) Methods of administering an aripiprazole injectable preparation
HK40077871A (en) Methods of administering an aripiprazole injectable preparation
OA19838A (en) Capsid assembly modulator dosing regimen.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40080999

Country of ref document: HK